|
|||||
|
|
Erythema nodosum arising during everolimus therapy for tuberous sclerosis complex |
|
| Authors: | Eloise R. Galligan BA Lindsey Fix MD Laura E. Levin MD Lisa Imundo MD Darrell J. Yamashiro MD PhD Maria C. Garzon MD |
| Affiliation: | 1. College of Physicians and Surgeons, Columbia University, New York, NY, USA;2. Department of Dermatology, Columbia University, New York, NY, USA;3. Department of Rheumatology, Columbia University, New York, NY, USA;4. Department of Pediatrics, Columbia University, New York, NY, USA;5. Department of Pathology and Cell Biology, Columbia University, New York, NY, USA |
| Abstract: | Indications for everolimus and other drugs within the mammalian target of rapamycin inhibitor class have recently expanded to include tuberous sclerosis complex. Everolimus is generally well tolerated, but it is important for physicians to identify and manage associated cutaneous adverse effects. We report the first case of a child developing erythema nodosum while undergoing everolimus therapy. |
| Keywords: | erythema nodosum everolimus mTOR inhibitor panniculitis |